Swiss biopharmaceutical concern Roche has signed a cooperation agreement with biotechnology company Regeneron Pharmaceuticals (USA). The American company has developed an antibody-based drug for the treatment of coronavirus infection, which can be used both to help people who are ill and to prevent COVID-19 in healthy people.

This drug is in the third stage of clinical trials until the end of September. By the end of the year it is planned to obtain registration and establish industrial production of the drug at Roche's facilities in the USA and Europe. Regeneron will supply the drug to the domestic market in the United States and Roche around the world. At the same time, the Swiss concern will be obliged to pay 50% of the revenue from the sale of the drug to its American partner.